China launches Tianwen-2 space probe to collect samples from asteroid near Mars
China has launched a space probe that will travel to an asteroid near Mars to collect samples and find potential "groundbreaking" results.
The Tianwen-2 probe launched Thursday from the Xichang Satellite Launch Center in southwest China's Sichuan Province aboard the workhorse Long March 3-B rocket, according to the China National Space Administration (CNSA).
The target of the Tianwen-2 will be different from its predecessor, the Tianwen-1, which launched a year ago and landed on Mars.
Tianwen-2 will be aiming for the asteroid 2016 HO3, which is also known as 469219 Kamoʻoalewa, to bring back samples.
China's Secret Weapon In The Space Race Is Already Hurting Us
The proposed 10-year plan would involve more than just this space mission as China continues to look to expand into space.
Read On The Fox News App
Zhang Rongqiao, chief designer of the Tianwen-1, told China Central Television he plans to implement the "Tianwen-3" Mars sampling return mission in 2028, while the "Tianwen-4" will head toward Jupiter.
According to The Associated Press, the asteroids, chosen for their relatively stable orbits, will hopefully offer clues about the formation of Earth, such as the origins of water.
Us Prepares To Deorbit International Space Station Amid China Competition
Samples from 2016HO3 are due to be returned in about two years.
Even if the CNSA is going to distribute these samples to international partners like they have on previous missions, NASA wouldn't be able to receive any samples.
A law passed in 2011, known as the Wolf Amendment, restricts NASA from having any cooperation with the CNSA.
China also operates the three-person Tiangong, or "Heavenly Palace," space station.
This gives China a step in the right direction to become a major force in the exploration of space.
Its permanent station was created after being excluded from the International Space Station over U.S. national security concerns.
The Associated Press contributed to this storyOriginal article source: China launches Tianwen-2 space probe to collect samples from asteroid near Mars
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
41 minutes ago
- Yahoo
2025 ASCO ｜Oral Presentation: Disitamab Vedotin Achieves Stellar Efficacy as First-Line Therapy for HER2-Expressing Locally Advanced or Metastatic Gastric Cancer
YANTAI, China, June 2, 2025 /PRNewswire/ -- On June 2 (Chicago time), in an oral presentation at the 2025 ASCO Annual Meeting, Dr. Lin Shen from Beijing Cancer Hospital presented the results of a Phase 2 clinical study conducted in China evaluating the efficacy and safety of disitamab vedotin (DV), developed by Remegen Co., Ltd., and toripalimab (PD-1) combined with CAPOX or trastuzumab as the first-line therapy for HER2-expressing patients with locally advanced or metastatic (la/m) gastric cancer. Comparing to the control group who received standard-of-care therapy, the DV combination therapy demonstrated clinically meaningful efficacy improvement, potentially to benefit patients who are non-responders to traditional targeted therapies. The data presented are from the Phase 2 part of a randomized, multi-cohort, seamlessly connecting Phase 2/3 study, which enrolled systematic chemotherapy-native patients with different HER2 expression levels. As of April 7, 2025, the results showed: Among HER2-overexpressing gastric cancer patients, compared to the PD-1-trastuzumab-CAPOX combination therapy, DV and PD-1 + chemotherapy as well as DV and PD-1 + trastuzumab both demonstrated statistically significant efficacy and favorable safety profiles. Objective response rate (ORR): 66.7% vs 82.4% vs 68.8%; Median progression-free survival (mPFS): NR vs NR vs 14.1 months, with risk of disease progression decreasing by 54%（HR=0.46）and 41% (HR: 0.59); 12-month PFS rate: 66.3%, 67% and 53.6%； Common TRAEs of grade 3-5: diarrhea, neutrophil count decreased, platelet count decreased, etc. In patients with HER2-low-expressing gastric cancer, promising efficacy was observed with DV + PD-1 + CAPOX comparing to PD-1 + CAPOX, with a manageable safety profile. ORR: 72.0% vs 47.8%; mPFS: 9.9 vs 7.2 months, with risk of disease progression decreasing by 31% (HR: 0.69); Common TRAEs of grade 3-5: diarrhea, neutrophil count decreased, platelet count decreased, etc. Dose optimization conducted in patients with HER2-median/low-expressing gastric cancer. Compared to PD-1 + CAPOX, DV at 2.5 mg/kg or 2.0 mg/kg combined with PD-1 + reduced-dose CAPOX showed significant efficacy, and better safety over the full-dose chemotherapy. ORR: 71.4% vs 66.7% vs 56.3%; 6-month PFS rate: 71.4%，72.7% and 53.3%. Globally, this is the first study to explore the triple combination therapy of "HER2 ADC + PD-1 + targeted medication" as first-line treatment of patients with la/m gastric cancer, pioneering a new mode of synergistic therapy. The multi-cohort design of this study provides precision treatment regimen for gastric cancer patients with different level of HER2 expression. For the HER2-overexpressing gastric cancer patients, DV + PD-1 + trastuzumab has the potential to become the new standard first-line treatment; for the HER2-low-expressing gastric cancer patients, DV + PD-1 + chemotherapy has the potential to fill the treatment gap of these patients. Based on the data obtained from the phase 2 study, the phase 3 clinical study of the triple combination therapy in patients with HER2-median/low-expressing gastric cancer has been initiated in April, 2025, in which 616 participants were planned to be enrolled, to further validate the efficacy of the DV combination therapy. Gastric cancer is the fifth most common malignant tumor in the world, and China accounts for about 42.6% of new cases and 45.0% of deaths worldwide. HER2 is an important target in the treatment of gastric cancer, while the traditional targeted drug trastuzumab is only effective in the population with high expression (IHC 3+ or IHC 2+/FISH+), and can easily become resistant. There is a lack of effective targeted therapy options for patients with low/median HER2 expression (IHC 1+ or IHC 2+/FISH-), and the efficacy of chemotherapy combined with immunotherapy is not satisfactory. As the first domestic HER2-targeted ADC drug in China, DV not only precisely kills tumor cells with HER2 over expression but also attacks adjacent cells with HER2 low expression through the bystander effect. Preclinical studies have also shown that the combination of DV with PD-1 inhibitor and trastuzumab can enhance anti-tumor activity. View original content to download multimedia: SOURCE RemeGen Co., Ltd Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Historic university garden vandalized in apparent anti-Israel statement: 'Don't waste your tears'
Hundreds of the University of Michigan's iconic peonies were reportedly cut in an act of vandalism – apparently perpetrated by at least one unidentified pro-Palestinian agitator. The Ann Arbor school's W.E. Upjohn Peony Garden, located in Nichols Arboretum, is home to North America's largest collection of historic herbaceous peonies, according to The Associated Press – and it boasts about 800 plants with 10,000 flowers at peak bloom. However, about 250 – or one-third of them – were found Sunday morning with most of their flowers cut off. Anti-israel Protesters Torch Diplomas Outside Columbia University On Graduation Day While no group has taken credit for the gratuitous act of destruction, according to the university's Division of Public Safety & Security (DPSS), papers found around the site outlined the apparent motive. "Plant lives don't matter. Human lives do," the papers read in part. "Stop the war. Resist Imperialism." Read On The Fox News App "Palestinian lives deserve to be cared for. More than these flowers," they continue. "Don't waste your tears on the peonies. They are not even dead and will grow again next spring." "Make no mistake, the criminal tactics used in the recent act of vandalism at Nichols Arboretum are wholly unacceptable," read a statement by the university. "We unequivocally condemn the destruction of property and any act of vandalism on our campus," the statement continued. "Damaging a beloved community space intended to foster reflection and bring hope to the whole community is counter productive. We urge all community members to channel their voices through constructive and meaningful dialogue." University Of Michigan President's Home Spray-painted With Anti-israel Messages: 'Intifada' UMich is no stranger to acts of vandalism by anti-Israel agitators – university President Santa Ono's home and the surrounding area were spray-painted with the words "intifada" and "coward" in October. The Upjohn Garden incident also transpired on the same day as an alleged terrorist attack on a pro-Israel demonstration in Boulder, Colorado, that left multiple people injured. The suspect, Mohamad Sabry Soliman, "stated that he wanted to kill all Zionist people," according to a federal complaint. The DPSS is actively investigating the matter, which the school describes as a "criminal incident." A Public Affairs representative for the university declined to comment further on the incident when reached by Fox News article source: Historic university garden vandalized in apparent anti-Israel statement: 'Don't waste your tears'
The Hill
2 hours ago
- The Hill
Senators itching for Trump green light to move on Russia sanctions
Senators in both parties are itching to move a bipartisan Russia sanctions package as fighting escalates in the region, but Republicans are waiting on a green light from President Trump. The effort to pass a robust sanctions package is hitting high gear. Trump and his allies are sounding a considerably more negative tone about Russian President Vladimir Putin, who has shown few signs of slowing down his battle against Ukraine. Some of Trump's closest allies, including Sen. Lindsey Graham (R-S.C.) are pushing hard to more aggressively target Putin. And both a stunning operation by Ukraine and an escalation of attacks by Russia are giving more senators the impetus to act. But while Trump's grown more vocal about Putin's unwillingness to move toward a peace deal, he has declined to throw in his lot with the sanctions bill, which has more than 80 cosponsors in the upper chamber — effectively keeping it on ice for the time being. 'We're working with the White House. … We are prepared to move forward as soon as they feel like the timing is right. They're leading,' said Sen. Markwayne Mullin (R-Okla.), who, along with Graham, has had ongoing talks with Trump about the sanctions bill. 'We don't want to get in front of the White House.' 'We don't want to interfere in the middle of negotiations. … If we have to do this to get their attention, we most definitely will. We're 100 percent willing and able to move forward with it,' Mullin continued. 'It doesn't do us any good if we pass it in the House, pass it in the Senate and then the president is like, 'Hold on a second guys.' It puts him in a bad position [and it] puts us in a bad position.' Senate Majority Leader John Thune (R-S.D.) told reporters that the bill could hit the floor during the current four-week work period. '[The White House is] still hopeful they'll be able to strike some sort of a deal, but … there's a high level of interest here in the Senate on both sides of the aisle in moving on it,' he said. 'I think a genuine interest in doing something to make clear to Russia that they need to come to the table. … I think that would have a big impact.' The package in question would implement some of the harshest sanctions possible on some of Moscow's top trading partners, including a 500 percent tariff on nations that purchase oil, gas, uranium and other goods from Russia. China and India are Russia's biggest customers for those items, accounting for 70 percent of Russia's energy exports. Graham, one of the leading proponents of the legislation, labeled it as 'the most draconian bill I've ever seen in my life in the Senate.' He also told The Associated Press that he crafted it in coordination with Trump's advisers and last week said he expected the Senate to start moving the bill this week. Nevertheless, Trump has remained non-committal, even though he has increased his criticism of Putin in recent weeks. 'I don't know. I'll have to see it,' he said on Friday when asked about the proposal. The push comes on the heels of Graham's visit to Kyiv, where he and Sen. Richard Blumenthal (D-Conn.) met with Ukrainian President Volodymyr Zelensky, and then Paris, where he spoke with French President Emmanuel Macron to discuss the latest state of play in the war. According to the South Carolina Republican, the only steps Putin is taking in the coming months to end the war is by trying to defeat the Ukrainians. 'We saw credible evidence of a summer or early fall invasion, a new offensive by Putin,' Graham told the Associated Press. 'He's preparing for more war.' Russian, Ukrainian and U.S. officials convened in Istanbul for a second round of peace talks on Monday, where the two warring nations agreed to trade thousands of dead and seriously injured troops. However, there were no signs of progress toward concluding the three-year-old war. The talks took place only days after Ukraine launched a stunning drone offensive that destroyed 40 Russian warplanes at air bases across the country. The total represents one-third of the Russian bomber fleet and happened after Ukraine smuggled 117 drones deep into Russia in an operation that took 18 months of planning. Russia, meanwhile, launched a heavy attack on Ukraine on Sunday. According to the Ukrainian air force, Russia launched 472 drones against Ukraine, marking the highest total since the beginning of the war. The intense back-and-forth in recent days is inspiring more lawmakers to push for action. 'I hate to say that I'm glad the president is seeing … Putin for the evil murderer that he is, but now we have to have a consequence for it,' Sen. Thom Tillis (R-N.C.) said, adding that he would vote for the sanctions package 'in a heartbeat.' While Republicans wait on word from the president, Democrats have no such patience. 'The single best thing President Trump can do to strengthen Ukraine's hand right now is to show that the U.S. stands firmly behind them and squarely against Russia. But so far, Trump has not done that,' Senate Minority Leader Chuck Schumer (D-N.Y.) said on the floor Monday. 'Where is Donald Trump's backbone? Where is his conviction? Where's that toughness he likes to project?' Schumer asked. 'Frankly, senators from both sides of the aisle are getting tired of Donald Trump's wishy-washy approach to Putin. If Donald Trump won't stand up to him, the Senate must.' The New York Democrat also called the sanctions package a 'hammer blow' to Moscow. 'It's very much needed, and it's needed now,' he added.
